Application of neuroendoscopic surgical techniques in the assessment and treatment of cerebral ventricular infection
Feng Guan
WeiCheng Peng
Hui Huang
ZuYuan Ren
ZhenYu Wang
JiDi Fu
YingBin Li
FengQi Cui
Bin Dai
GuangTong Zhu
ZhiYong Xiao
BeiBei Mao
ZhiQiang Hu
摘要：Cerebral ventricular infection (CVI) is one of the most dangerous complications in neurosurgery because of its high mortality and dis-ability rates. Few studies have examined the application of neuroendoscopic surgical techniques (NESTs) to assess and treat CVI. This multicenter, retrospective study was conducted using clinical data of 32 patients with CVI who were assessed and treated by NESTs in China. The patients included 20 men and 12 women with a mean age of 42.97 years. NESTs were used to obliterate intraventricular debris and pus, fenestrate or incise the intraventricular compartment and reconstruct cerebrospinal fluid circulation, and remove artificial materi-al. Intraventricular irrigation with antibiotic saline was applied after neuroendoscopic surgery (NES). Secondary hydrocephalus was treated by endoscopic third ventriculostomy or a ventriculoperitoneal shunt. Neuroendoscopic findings of CVI were used to classify patients into Grade I (n = 3), Grade II (n = 13), Grade III (n = 10), and Grade IV (n = 6) CVI. The three patients with grade I CVI underwent one NES, the 23 patients with grade II/III CVI underwent two NESs, and patients with grade IV CVI underwent two (n = 3) or three (n = 3) NESs. The imaging features and grades of neuroendoscopy results were positively related to the number of neurosurgical endoscopic procedures. Two patients died of multiple organ failure and the other 30 patients fully recovered. Among the 26 patients with secondary hydrocephalus, 18 received ventriculoperitoneal shunt and 8 underwent endoscopic third ventriculostomy. There were no recurrences of CVI during the 6- to 76-month follow-up after NES. Application of NESTs is an innovative method to assess and treat CVI, and its neuroendoscopic classi-fication provides an objective, comprehensive assessment of CVI. The study trial was approved by the Institutional Review Board of Beijing Shijitan Hospital, Capital Medical University, China.
机标关键词：
资助基金：the Capital Health Research and Development of Special Funding Support of China, (No. 2011-2008-06)Capital Characteristic Clinical Application Research of China, (No. Z131107002213044)Beijing Municipal Administration of Hospitals Incubating Program of China, (No. PX2019026 (to FG). 2008-06)Beijing Municipal Ad-ministration of Hospitals Incubating Program of China, (No. PX2019026 (to FG). The funders had no involvement in study design)
论文发表日期：2019-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：9( 2095-2103 )
英文信息